Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers June 26, 2017
Pharmacy Choice - Pharmaceutical News - DGAP-News: MorphoSys Announces First Results from Phase 1 Study with Lanthipeptide MOR107 in Healthy Volunteers (english) - June 26, 2017

Pharmacy News Article

 5/19/17 - DGAP-News: MorphoSys Announces First Results from Phase 1 Study with Lanthipeptide MOR107 in Healthy Volunteers (english)
MorphoSys Announces First Results from Phase 1 Study with Lanthipeptide MOR107 in Healthy Volunteers

^
DGAP-News: MorphoSys AG / Key word(s): Study results
MorphoSys Announces First Results from Phase 1 Study with Lanthipeptide
MOR107 in Healthy Volunteers (news with additional features)

19.05.2017 / 07:30
The issuer is solely responsible for the content of this announcement.

-

Planegg/Munich, Germany, May 19, 2017

MorphoSys Announces First Results from Phase 1 Study with Lanthipeptide
MOR107 in Healthy Volunteers

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY)
announced today the completion of the first part of a phase 1 clinical study
in healthy volunteers with the investigational drug candidate MOR107 ahead
of schedule. MOR107 is a selective agonist of the angiotensin II receptor
type 2 (AT2-R), and is a lanthipeptide based on the proprietary technology
platform of MorphoSys's subsidiary Lanthio Pharma. MOR107 is also the first
lanthipeptide in MorphoSys's clinical pipeline.

Based on an initial analysis of subjects enrolled to date, in all doses
tested in this first-in-human trial, based on blinded data, there were no
clinically relevant safety events seen, and all adverse events observed thus
far were mild and transient in nature. Moreover a dose-dependent
pharmacokinetic profile for MOR107 was observed.

"We are very pleased with the initial data from the first part of the phase
1 clinical study of our MOR107 lanthipeptide in healthy volunteers conducted
by our subsidiary Lanthio Pharma", commented Dr. Malte Peters, Chief
Development Officer of MorphoSys AG. "Preparations for the second part of
the trial are ongoing."

The study has been conducted by MorphoSys's fully owned subsidiary Lanthio
Pharma B.V., Groningen, Netherlands.

About Lanthio Pharma and MOR107
Lanthio Pharma B.V., a wholly owned subsidiary of MorphoSys AG since 2015,
is a Dutch biopharmaceutical company committed to developing and
commercializing therapeutic peptides to activate difficult to target
receptors (e.g. GPCRs). With its proprietary technology, Lanthio Pharma is
generating lanthipeptides, a new class of cyclical peptide molecules which
have been engineered with the intention of achieving enhanced stability and
selectivity. Research is focused on the protective arm of the
Renin-Angiotensin System (RAS). Lanthio Pharma has currently two programs
targeting the two key receptors in this pathway. The lead product is MOR107
(formerly LP2-3), a selective angiotensin II receptor type 2 receptor
(AT2-R) agonist. MOR107 is currently being investigated in a
"first-in-human" phase 1 clinical study in healthy volunteers.

About MorphoSys
MorphoSys is committed to developing exceptional new treatments for patients
suffering from serious diseases. A leader in the field of therapeutic
antibodies today, MorphoSys is driven by the ambition of creating the most
valuable pipeline of biopharmaceuticals in the biotechnology industry. Based
on its proprietary technology platforms, MorphoSys, together with its
partners, has built a therapeutic pipeline of more than 110 programs in R&D,
around a quarter of which is currently in clinical development.
In its proprietary development segment, MorphoSys, alone or with partners,
is developing new therapeutic candidates, mainly focusing on cancer and
inflammation. In its partnered discovery segment, MorphoSys uses its
technologies to discover new drug candidates for pharmaceutical partners and
participates from the programs' further development success, through
success-based payments and royalties. MorphoSys is listed on the Frankfurt
Stock Exchange under the symbol MOR. For regular updates about MorphoSys,
visit http://www.morphosys.com.

HuCAL(R), HuCAL GOLD(R), HuCAL PLATINUM(R), CysDisplay(R), RapMAT(R),
arYla(R),
Ylanthia(R), 100 billion high potentials(R), Slonomics(R), Lanthio Pharma(R)
and LanthioPep(R) are registered trademarks of the MorphoSys Group.

This communication contains certain forward-looking statements concerning
the MorphoSys group of companies. The forward-looking statements contained
herein represent the judgment of MorphoSys as of the date of this release
and involve risks and uncertainties. Should actual conditions differ from
the Company's assumptions, actual results and actions may differ from those
anticipated, MorphoSys does not intend to update any of these
forward-looking statements as far as the wording of the relevant press
release is concerned.

For more information, please contact:

MorphoSys AG
Anke Linnartz
Head of Corporate Communications & IR

Jochen Orlowski
Associate Director Corporate Communications & IR

Alexandra Goller
Senior Manager Corporate Communications & IR

Tel: +49 (0) 89 / 899 27-404
investors@morphosys.com


-

Additional features:

Document: http://n.eqs.com/c/fncls.ssp?u=DIKRWJIXQN
Document title: Media Release

-

19.05.2017 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de

-

   Language:    English
   Company:     MorphoSys AG
                Semmelweisstr. 7
                82152 Planegg
                Germany
   Phone:       +49 (0)89 899 27-0
   Fax:         +49 (0)89 899 27-222
   E-mail:      investors@morphosys.com
   Internet:    www.morphosys.com
   ISIN:        DE0006632003
   WKN:         663200
   Indices:     TecDAX
   Listed:      Regulated Market in Frankfurt (Prime Standard); Regulated
                Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover,
                Munich, Stuttgart, Tradegate Exchange



   End of News    DGAP News Service
-

575395 19.05.2017








Copyright dpa-AFX.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

LIVE ONLINE CE

Last Chance
Jun 27: Medication Adherence: To Take or Not to Take…That is the Problem
Last Chance
Jun 28: Mobile Applications for Pharmacists: Tools That Help Pharmacies be Successful
Jun 29: REMS Drugs & The Practice of Pharmacy: A Program in Law and Risk Management
Jul 02: HIV Medications: Newer Drugs, Newer Guidelines
Jul 03: Management of Major Depressive Disorders
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.



Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415